Sign in to view content

Baseline Factors Associated With 1-Year Outcomes in Phase III Comparison of SB11 (Approved Ranibizumab Biosimilar) With Reference Ranibizumab in nAMD

Neil M. Bressler, MD

Video
Published 2022

Related

Primary Analysis Results of the Phase 3 Archway Trial of the Port Delivery System With Ranibizumab (PDS) for Patients With Neovascular AMD
Peter A. Campochiaro, MD
Annual Meeting Talks
2020
Episode 19: LEAD Trial for Use of Nanopulse Laser for Dry AMD with Dr. Robyn Guymer
Keyvan Koushan, MD, FRCSC
Member Podcasts
2018
Episode 13: Long-Term Treatment of Wet AMD by 50+ Anti-VEGF Injections with Dr. Sean Adrean
Keyvan Koushan, MD, FRCSC
Member Podcasts
2018

Category: AMD-Neovascular

See more